• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤溶酶原激活物抑制剂-1 处于活性构象及具有正常热力学稳定性的晶体结构。

Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability.

机构信息

Department of Molecular Biology, Aarhus University, Aarhus C, Denmark.

出版信息

J Biol Chem. 2011 Aug 26;286(34):29709-17. doi: 10.1074/jbc.M111.236554. Epub 2011 Jun 21.

DOI:10.1074/jbc.M111.236554
PMID:21697084
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3191012/
Abstract

The serpin plasminogen activator inhibitor-1 (PAI-1) is a crucial regulator in fibrinolysis and tissue remodeling. PAI-1 has been associated with several pathological conditions and is a validated prognostic marker in human cancers. However, structural information about the native inhibitory form of PAI-1 has been elusive because of its inherent conformational instability and rapid conversion to a latent, inactive structure. Here we report the crystal structure of PAI-1 W175F at 2.3 Å resolution as the first model of the metastable native molecule. Structural comparison with a quadruple mutant (14-1B) previously used as representative of the active state uncovered key differences. The most striking differences occur near the region that houses three of the four mutations in the 14-1B PAI-1 structure. Prominent changes are localized within a loop connecting β-strand 3A with the F helix, in which a previously observed 3(10)-helix is absent in the new structure. Notably these structural changes are found near the binding site for the cofactor vitronectin. Because vitronectin is the only known physiological regulator of PAI-1 that slows down the latency conversion, the structure of this region is important. Furthermore, the previously identified chloride-binding site close to the F-helix is absent from the present structure and likely to be artifactual, because of its dependence on the 14-1B mutations. Instead we found a different chlorine-binding site that is likely to be present in wild type PAI-1 and that more satisfactorily accounts for the chlorine stabilizing effect on PAI-1.

摘要

丝氨酸蛋白酶抑制剂 plasminogen 激活物抑制剂-1(PAI-1)是纤维蛋白溶解和组织重塑的关键调节因子。PAI-1 与几种病理状况有关,是人类癌症中经过验证的预后标志物。然而,由于其固有构象不稳定性和快速转化为潜伏的、无活性的结构,关于 PAI-1 的天然抑制形式的结构信息一直难以捉摸。在这里,我们报告了 PAI-1 W175F 的晶体结构,分辨率为 2.3Å,这是第一个亚稳态天然分子的模型。与之前用作活性状态代表的四重突变体(14-1B)的结构比较揭示了关键差异。最显著的差异发生在容纳 14-1B PAI-1 结构中四个突变中的三个的区域附近。明显的变化局限于连接β-链 3A 与 F 螺旋的环内,在新结构中不存在先前观察到的 3(10)-螺旋。值得注意的是,这些结构变化发生在与辅因子 vitronectin 的结合位点附近。因为 vitronectin 是唯一已知的能够减缓潜伏转化速度的 PAI-1 生理调节剂,所以这个区域的结构很重要。此外,先前在 F 螺旋附近确定的氯结合位点不存在于当前结构中,并且由于其依赖于 14-1B 突变,可能是人为的。相反,我们发现了一个不同的氯结合位点,可能存在于野生型 PAI-1 中,并且更能解释氯对 PAI-1 的稳定作用。

相似文献

1
Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability.纤溶酶原激活物抑制剂-1 处于活性构象及具有正常热力学稳定性的晶体结构。
J Biol Chem. 2011 Aug 26;286(34):29709-17. doi: 10.1074/jbc.M111.236554. Epub 2011 Jun 21.
2
The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.纤溶酶原激活物抑制剂1的活性构象,一种控制纤维蛋白溶解和细胞黏附的药物靶点。
Structure. 1999 Feb 15;7(2):111-8. doi: 10.1016/S0969-2126(99)80018-5.
3
Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.纤溶酶原激活物抑制剂1。天然丝氨酸蛋白酶抑制剂的结构,与其他构象的比较及其对丝氨酸蛋白酶抑制剂失活的影响。
J Mol Biol. 2000 Mar 31;297(3):683-95. doi: 10.1006/jmbi.2000.3604.
4
Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.噬菌体展示的高突变纤溶酶原激活物抑制剂1(PAI-1)文库证明,潜伏期转变和蛋白酶抑制过程中PAI-1的不同结构要求。
J Mol Biol. 2001 Jan 26;305(4):773-83. doi: 10.1006/jmbi.2000.4356.
5
Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.干扰丝氨酸蛋白酶抑制剂(serpins)的抑制机制:1型纤溶酶原激活物抑制剂裂解形式与反应中心环肽形成的复合物的晶体结构
Structure. 1998 May 15;6(5):627-36. doi: 10.1016/s0969-2126(98)00064-1.
6
The importance of helix F in plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1中F螺旋的重要性。
Biochim Biophys Acta. 2000 Jan 3;1476(1):20-6. doi: 10.1016/s0167-4838(99)00224-1.
7
High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling.稳定的1型纤溶酶原激活物抑制剂变体14-1B蛋白酶切割形式的高分辨率结构:用于详细相互作用研究和建模的新工具。
Protein Sci. 2008 Oct;17(10):1844-9. doi: 10.1110/ps.036707.108. Epub 2008 Aug 25.
8
Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.小分子抑制剂与纤溶酶原激活物抑制剂-1 结合的机制特征和晶体结构。
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4941-9. doi: 10.1073/pnas.1216499110. Epub 2013 Dec 2.
9
Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.四种抗人1型纤溶酶原激活物抑制剂单克隆抗体的表位作图:对抗体介导的PAI-1中和作用及与玻连蛋白结合的意义
Eur J Biochem. 2001 Feb;268(4):1095-106. doi: 10.1046/j.1432-1327.2001.2680041095.x.
10
Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties.纤溶酶原激活物抑制剂-1中一个靶位点的鉴定,该位点可在中和其抑制特性的同时,变构上调其抗黏附特性。
J Biol Chem. 2001 Jul 13;276(28):26243-8. doi: 10.1074/jbc.M008241200. Epub 2001 May 7.

引用本文的文献

1
Deep mutational scanning and massively parallel kinetics of plasminogen activator inhibitor-1 functional stability to probe its latency transition.深突变扫描和纤溶酶原激活物抑制剂-1 功能稳定性的大规模并行动力学,以探索其潜伏态转变。
J Biol Chem. 2022 Dec;298(12):102608. doi: 10.1016/j.jbc.2022.102608. Epub 2022 Oct 17.
2
A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?纤溶酶原激活物抑制剂-1 的综述及其(病理)生理学作用:靶向还是不靶向?
Int J Mol Sci. 2021 Mar 8;22(5):2721. doi: 10.3390/ijms22052721.
3
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.心血管疾病中靶向纤溶酶原激活物抑制剂-1:纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
4
Dissecting molecular details and functional effects of the high-affinity copper binding site in plasminogen activator Inhibitor-1.解析纤溶酶原激活物抑制剂-1 高亲和力铜结合位点的分子细节和功能效应。
Protein Sci. 2021 Mar;30(3):597-612. doi: 10.1002/pro.4017. Epub 2021 Jan 13.
5
Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy.纤溶酶原激活物抑制剂-1:类脂质渐进性坏死发病中的一个潜在病因学角色。
Int Wound J. 2020 Dec;17(6):1902-1908. doi: 10.1111/iwj.13480. Epub 2020 Oct 11.
6
Structural Insights into the Mechanism of a Nanobody That Stabilizes PAI-1 and Modulates Its Activity.一种纳米抗体稳定 PAI-1 并调节其活性的机制的结构见解。
Int J Mol Sci. 2020 Aug 15;21(16):5859. doi: 10.3390/ijms21165859.
7
Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.两种抑制纤溶酶原激活物抑制剂-1(PAI-1)活性的纳米抗体的分子机制揭示了PAI-1/纤溶酶原激活剂相互作用不同阶段的调节作用。
J Thromb Haemost. 2020 Mar;18(3):681-692. doi: 10.1111/jth.14716. Epub 2020 Feb 20.
8
Characterization of an Extensive Interface on Vitronectin for Binding to Plasminogen Activator Inhibitor-1: Adoption of Structure in an Intrinsically Disordered Region.鉴定纤连蛋白与纤溶酶原激活物抑制剂-1广泛结合界面:在无规则区域中采用结构。
Biochemistry. 2019 Dec 24;58(51):5117-5134. doi: 10.1021/acs.biochem.9b00605. Epub 2019 Dec 16.
9
Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1.发现并鉴定一种可选择性调节纤溶酶原激活物抑制剂-1 抑制活性的抗体。
Sci Rep. 2019 Feb 7;9(1):1605. doi: 10.1038/s41598-019-38842-x.
10
Serpine1 Knockdown Enhances MMP Activity after Flexor Tendon Injury in Mice: Implications for Adhesions Therapy.丝氨酸蛋白酶抑制剂 1 基因敲低增强小鼠屈肌腱损伤后基质金属蛋白酶的活性:对粘连治疗的启示。
Sci Rep. 2018 Apr 11;8(1):5810. doi: 10.1038/s41598-018-24144-1.

本文引用的文献

1
Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.金属会影响人纤溶酶原激活物抑制剂-1 的结构和活性。二。结合亲和力和构象变化。
Protein Sci. 2011 Feb;20(2):366-78. doi: 10.1002/pro.567.
2
Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.金属影响人纤溶酶原激活物抑制剂-1 的结构和活性。I. 稳定性和蛋白酶抑制的调节。
Protein Sci. 2011 Feb;20(2):353-65. doi: 10.1002/pro.568.
3
PHENIX: a comprehensive Python-based system for macromolecular structure solution.PHENIX:一个基于Python的用于大分子结构解析的综合系统。
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21. doi: 10.1107/S0907444909052925. Epub 2010 Jan 22.
4
XDS.XDS.(这个词如果没有更多背景信息,很难准确翻译出更有意义的内容,直接保留原文是一种处理方式,或者音译为“克斯达斯”之类,但感觉都不太符合常规翻译场景,你可以补充更多关于这个词的信息以便我更准确翻译 )
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32. doi: 10.1107/S0907444909047337. Epub 2010 Jan 22.
5
Biochemical properties of plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1的生化特性。
Front Biosci (Landmark Ed). 2009 Jan 1;14(4):1337-61. doi: 10.2741/3312.
6
Alignment of protein structures in the presence of domain motions.存在结构域运动时蛋白质结构的比对
BMC Bioinformatics. 2008 Aug 27;9:352. doi: 10.1186/1471-2105-9-352.
7
High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling.稳定的1型纤溶酶原激活物抑制剂变体14-1B蛋白酶切割形式的高分辨率结构:用于详细相互作用研究和建模的新工具。
Protein Sci. 2008 Oct;17(10):1844-9. doi: 10.1110/ps.036707.108. Epub 2008 Aug 25.
8
Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.构象敏感配体揭示的1型纤溶酶原激活物抑制剂活性形式之间的结构差异。
J Biol Chem. 2008 Jun 27;283(26):18147-57. doi: 10.1074/jbc.M709455200. Epub 2008 Apr 24.
9
A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity.缺乏生长调节素B结构域的玻连蛋白缺失突变体表现出纤溶酶原激活物抑制剂-1结合活性。
J Biol Chem. 2008 Apr 18;283(16):10297-309. doi: 10.1074/jbc.M708017200. Epub 2008 Jan 3.
10
PAI-1 - a potential therapeutic target in cancer.纤溶酶原激活物抑制剂-1——癌症的一个潜在治疗靶点。
Curr Drug Targets. 2007 Sep;8(9):1030-41. doi: 10.2174/138945007781662346.